Not applicableLooking for participantsNCT06272864What this trial is testingBostonGene and Exigent Genomic INsight StudyWho this might be right forBreast CancerNon-small Cell Lung CancerMelanoma+1 more BostonGene 400
Early research (Phase 1)Looking for participantsNCT07517198What this trial is testingDose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsWho this might be right forSolid TumorSmall Cell Lung Cancer (SCLC)High Grade Neuroendocrine Cancer+9 more Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. 40
Not applicableStudy completedNCT06495008What this trial is testingTaste and Smell Dysfunction in Patients More Than Two Years After Start of Immune Checkpoint Inhibitor TherapyWho this might be right forMelanomaNon-small Cell Lung Cancer (NSCLC)Urogenital Cancers University Medical Center Groningen 101
Not applicableUnknownNCT04789252What this trial is testingHeterogeneity of Dendritic Cells in Colon and Non-small Cell Lung CancerWho this might be right forNon-small Cell Lung Cancer University of Milano Bicocca 64
Large-scale testing (Phase 3)Study completedNCT00136864What this trial is testingPositron Emission Tomography (PET) Imaging in Stage III Non-small Cell Lung Cancer (PET START Trial)Who this might be right forNon-Small-Cell Lung Carcinoma Ontario Clinical Oncology Group (OCOG) 310
Testing effectiveness (Phase 2)Study completedNCT01177397What this trial is testingStudy to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple MyelomaWho this might be right forMultiple MyelomaDiffuse Large B-Cell LymphomaGlioblastoma Multiforme+4 more Celgene 226
Not applicableStudy completedNCT01537991What this trial is testingISoToxic Accelerated RadioTherapy in Locally Advanced Non-small Cell Lung Cancer: The Phase I/II I-START TrialWho this might be right forLocally Advanced Non-small Cell Lung Cancer Lisette Nixon 81
Early research (Phase 1)Active Not RecruitingNCT05492682What this trial is testingSTART: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of CancerWho this might be right forMelanoma (Skin)Triple-Negative Breast CancerNon-Small Cell Lung Cancer+5 more Valo Therapeutics Oy 15
Testing effectiveness (Phase 2)Looking for participantsNCT05281406What this trial is testingAdditional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)Who this might be right forNSCLC Stage IIIBNSCLC Stage IV Goethe University 50
Large-scale testing (Phase 3)Looking for participantsNCT05317858What this trial is testingBlood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain MetsWho this might be right forBrain TumorNon Small Cell Lung Cancer InSightec 30
Early research (Phase 1)Study completedNCT00037817What this trial is testingPhase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural MalignanciesWho this might be right forAdvanced Esophageal CancersPrimary Small Cell Lung CancersNon-Small-Cell Lung Carcinoma+2 more National Cancer Institute (NCI) 34
Large-scale testing (Phase 3)Study completedNCT00409188What this trial is testingCancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)Who this might be right forNon-small Cell Lung Cancer EMD Serono 1,513
Testing effectiveness (Phase 2)Ended earlyNCT03094169What this trial is testingAVID100 in Advanced Epithelial CarcinomasWho this might be right forSolid Tumor, AdultTriple Negative Breast CancerHead and Neck Squamous Cell Carcinoma+1 more Formation Biologics 49
Testing effectiveness (Phase 2)Looking for participantsNCT05696782What this trial is testingQuick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung CancerWho this might be right forNonsmall Cell Lung Cancer Stage IIIUnresectable Non-Small Cell Lung CarcinomaNonsmall Cell Lung Cancer, Stage II Wake Forest University Health Sciences 28